Post
The privileged status of orphan medicines in Germany
In Germany, new measures have come into effect as part of the GKV-FinStG Act in 2022 that put into question …
Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks
The top 20 biopharmaceutical companies witnessed a promising first quarter (Q1) this year amid ongoing macroeconomic uncertainties, fluctuating interest rates, …
Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy
US-based Cerevance has secured $47m in Series B-1 extension funding to finance the upcoming Phase III trial for its lead …
Merck’s net income for Q1 2024 increases by 69% to $4.76bn
Merck & Co Inc (MSD) has reported a significant increase in net income attributable to shareholders, reaching $4.76bn in the …
Multiply Labs and GenScript partner on cell isolation automation
Robotics company Multiply Labs has partnered with global life-sciences service provider GenScript Biotech to automate the cell isolation phase in …
Cidara buys back rights to flu therapy from J&J for $85m
Cidara Therapeutics has entered into a definitive agreement with Johnson & Johnson (J&) to buy back the rights to its …
Inflation Reduction Act to have knock on effect on R&D, say biotech experts
Discussions surrounding the Inflation Reduction Act (IRA) are heating up as the 2026 effect date gets closer. Speakers at the …
Podcast #1: Doing Digital Deals in Life Sciences | Corporate Culture
Welcome to the first of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them …
Merck plans €300m investment at new German research centre
Merck KGaA (Merck) has announced an investment of more than €300m ($320.8m) in a new Life Science Research Center at …
Mundipharma to acquire rezafungin assets from Cidara Therapeutics
Mundipharma has signed an agreement to acquire all assets and rights related to antifungal candidate Rezzayo (rezafungin) from Cidara Therapeutics, …
Life science SMEs “heading out of the funding winter”
After what has been deemed a “funding winter” for life science SMEs, building a strong data package to attract larger …
Biogen reports net income of $393.4m in Q1 2024
Biogen has reported net income of $393.4m for the first quarter (Q1) of 2024, an increase from $387.6m in the …
FDA approves Utility Therapeutics’ Pivya tablets for UTIs
The US Food and Drug Administration (FDA) has approved Utility Therapeutics’ Pivya tablets, a new treatment for female adults with …
Investors anticipate “bounce-back” in European private investment
The Swiss biotech ecosystem suffers from a “weak public market”, said Francesco de Rubertis, a cofounder at Medicxi Ventures. Despite …
Novartis bags paediatric FDA label expansion for Lutathera
Novartis has received a US Food and Drug Administration (FDA) approval for the label expansion of its peptide receptor radionuclide …